A phase 2 substudy found retatrutide produced dose-related reductions in total body fat mass at 36 weeks versus placebo and dulaglutide in type 2 diabetes. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
A randomised crossover trial found 60 g/day of mixed nuts for 16 weeks lowered apolipoprotein B and VLDL and LDL particle numbers in older adults with overweight or obesity. PICO summary and expert commentary.
A post-hoc pooled analysis of three phase 3 trials testing tafolecimab 450 mg every four weeks for LDL-C lowering in Chinese adults with type 2 diabetes and hypercholesterolemia. PICO summary and expert commentary.
A post hoc mediation analysis of the SURMOUNT-1 to -4 trials found that gastrointestinal adverse events contributed only slightly (up to 3.1%) to tirzepatide-associated weight reduction, which was similar regardless of nausea. PICO summary and expert commentary.
A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
A 1-year randomised controlled trial of pharmacist-led collaborative care versus standard care in 400 adults with type 2 diabetes, reporting EQ-5D and visual analogue scale quality-of-life gains alongside a larger HbA1c reduction. PICO summary and expert commentary.
A small single-blind RCT testing whether a family-centered empowerment program improves patient-reported illness acceptance and self-management in type 2 diabetes. PICO summary and expert commentary.
A double-blind placebo-controlled crossover study finds metformin attenuates the postprandial blood pressure fall and reduces postprandial hypotension events in type 2 diabetes, alongside higher GLP-1, slower gastric emptying, and a faster heart rate. PICO summary and expert commentary.
An exploratory post hoc analysis suggesting tirzepatide improves insulin sensitivity more per unit weight loss than semaglutide in type 2 diabetes. PICO summary and expert commentary.
A secondary analysis of the COORDINATE-Diabetes trial found that up to one-third of patients with Type 2 diabetes and atherosclerotic cardiovascular disease stopped their SGLT-2i or GLP-1RA within 12 months, with cost and side effects among the cited reasons. PICO summary and expert commentary.